Unknown

Dataset Information

0

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.


ABSTRACT: OBJECTIVES:To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions. METHODS:This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel-group study comparing CT-P13 with RP (PLANETRA; NCT01217086). CT-P13 (3?mg/kg) was administered intravenously every 8?weeks from weeks 62 to 102. All patients received concomitant methotrexate. Endpoints included American College of Rheumatology 20% (ACR20) response, ACR50, ACR70, immunogenicity and safety. Data were analysed for patients who received CT-P13 for 102?weeks (maintenance group) and for those who received RP for 54?weeks and then switched to CT-P13 (switch group). RESULTS:Overall, 302 of 455 patients who completed the PLANETRA study enrolled into the extension. Of these, 158 had received CT-P13 (maintenance group) and 144 RP (switch group). Response rates at week 102 for maintenance versus switch groups, respectively, were 71.7% vs 71.8% for ACR20, 48.0% vs 51.4% for ACR50 and 24.3% vs 26.1% for ACR70. The proportion of patients with antidrug antibodies was comparable between groups (week 102: 40.3% vs 44.8%, respectively). Treatment-emergent adverse events occurred in similar proportions of patients in the two groups during the extension study (53.5% and 53.8%, respectively). CONCLUSIONS:Comparable efficacy and tolerability were observed in patients who switched from RP to its biosimilar CT-P13 for an additional year and in those who had long-term CT-P13 treatment for 2?years. TRIAL REGISTRATION NUMBER:NCT01571219; Results.

SUBMITTER: Yoo DH 

PROVIDER: S-EPMC5284338 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

Yoo Dae Hyun DH   Prodanovic Nenad N   Jaworski Janusz J   Miranda Pedro P   Ramiterre Edgar E   Lanzon Allan A   Baranauskaite Asta A   Wiland Piotr P   Abud-Mendoza Carlos C   Oparanov Boycho B   Smiyan Svitlana S   Kim HoUng H   Lee Sang Joon SJ   Kim SuYeon S   Park Won W  

Annals of the rheumatic diseases 20160429 2


<h4>Objectives</h4>To assess the efficacy and safety of switching from the infliximab reference product (RP; Remicade) to its biosimilar CT-P13 (Remsima, Inflectra) or continuing CT-P13 in patients with rheumatoid arthritis (RA) for an additional six infusions.<h4>Methods</h4>This open-label extension study recruited patients with RA who had completed the 54-week, randomised, parallel-group study comparing CT-P13 with RP (PLANETRA; NCT01217086). CT-P13 (3 mg/kg) was administered intravenously ev  ...[more]

Similar Datasets

| S-EPMC6850326 | biostudies-literature
| S-EPMC6187418 | biostudies-literature
| S-EPMC5284340 | biostudies-literature
| S-EPMC5867419 | biostudies-literature
| S-EPMC4830106 | biostudies-literature
| S-EPMC4984328 | biostudies-literature
| S-EPMC5640013 | biostudies-other
| S-EPMC4926778 | biostudies-literature
| S-EPMC7113200 | biostudies-literature
| S-EPMC7369127 | biostudies-literature